Candel Therapeutics Net Worth
Candel Therapeutics Net Worth Breakdown | CADL |
Candel Therapeutics Net Worth Analysis
Candel Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Candel Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Candel Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Candel Therapeutics' net worth analysis. One common approach is to calculate Candel Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Candel Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Candel Therapeutics' net worth. This approach calculates the present value of Candel Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Candel Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Candel Therapeutics' net worth. This involves comparing Candel Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Candel Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Candel Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Candel Therapeutics' net worth research are outlined below:
| Candel Therapeutics is way too risky over 90 days horizon | |
| Candel Therapeutics appears to be risky and price may revert if volatility continues | |
| Candel Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 31 K. Net Loss for the year was (37.94 M) with loss before overhead, payroll, taxes, and interest of (20.66 M). | |
| Candel Therapeutics currently holds about 86.78 M in cash with (34.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.0. | |
| Candel Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 30.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Candel Therapeutics Prostate Cancer Therapy Shows Promise |
Candel Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Candel Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Candel Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Candel Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Candel Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Candel Therapeutics backward and forwards among themselves. Candel Therapeutics' institutional investor refers to the entity that pools money to purchase Candel Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 64.4 K | Hb Wealth Management, Llc | 2024-09-30 | 56.7 K | Charles Schwab Investment Management Inc | 2024-09-30 | 46.8 K | Bank Of New York Mellon Corp | 2024-09-30 | 45 K | Goldman Sachs Group Inc | 2024-09-30 | 30.3 K | Barclays Plc | 2024-09-30 | 28.7 K | Simplex Trading, Llc | 2024-09-30 | 22.8 K | Virtu Financial Llc | 2024-06-30 | 22.6 K | Rhumbline Advisers | 2024-09-30 | 22.5 K | Northpond Ventures, Llc | 2024-09-30 | 1.9 M | Vanguard Group Inc | 2024-09-30 | 946.3 K |
Follow Candel Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 134.29 M.Market Cap |
|
Project Candel Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.92) | (0.97) | |
| Return On Capital Employed | (1.42) | (1.35) | |
| Return On Assets | (0.92) | (0.97) | |
| Return On Equity | (2.98) | (2.83) |
When accessing Candel Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Candel Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Candel Therapeutics' profitability and make more informed investment decisions.
Evaluate Candel Therapeutics' management efficiency
Candel Therapeutics has return on total asset (ROA) of (0.5231) % which means that it has lost $0.5231 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.8068) %, meaning that it created substantial loss on money invested by shareholders. Candel Therapeutics' management efficiency ratios could be used to measure how well Candel Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.97. Return On Capital Employed is expected to rise to -1.35 this year. At this time, Candel Therapeutics' Debt To Assets are quite stable compared to the past year. Asset Turnover is expected to rise to 0 this year, although the value of Non Currrent Assets Other will most likely fall to about 312.6 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.44 | 0.52 | |
| Tangible Book Value Per Share | 0.44 | 0.53 | |
| Enterprise Value Over EBITDA | (0.80) | (0.84) | |
| Price Book Value Ratio | 3.34 | 3.50 | |
| Enterprise Value Multiple | (0.80) | (0.84) | |
| Price Fair Value | 3.34 | 3.50 | |
| Enterprise Value | 29.9 M | 28.4 M |
Management at Candel Therapeutics focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Enterprise Value Revenue 821.9774 | Revenue 31 K | Revenue Per Share 0.001 | Return On Equity (4.81) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Candel Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Candel Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Candel Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Candel Therapeutics Corporate Filings
8K | 11th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 6th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 24th of May 2024 Other Reports | ViewVerify |
Candel Therapeutics Earnings per Share Projection vs Actual
Candel Therapeutics Corporate Management
| Francesca MD | Chief Officer | Profile | |
| LLM JD | Chief Officer | Profile | |
| Nathan Caffo | Chief Officer | Profile | |
| MS MD | Chief Officer | Profile | |
| FMEDSCI MD | CEO Pres | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Candel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Candel Therapeutics. If investors know Candel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Candel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.73) | Revenue Per Share 0.001 | Return On Assets (0.52) | Return On Equity (4.81) |
The market value of Candel Therapeutics is measured differently than its book value, which is the value of Candel that is recorded on the company's balance sheet. Investors also form their own opinion of Candel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Candel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Candel Therapeutics' market value can be influenced by many factors that don't directly affect Candel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Candel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Candel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Candel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.